Pharmacokinetics of Orally Inhaled Drug Products

AAPS Journal

Volumn 17, Issue 3, 2015, Pages 769-775

  Hochhaus, Günther ^a   Horhota, Stephen ^b   Hendeles, Leslie ^a   Suarez, Sandra ^c   Rebello, Juliet ^d  

^a UNIVERSITY OF FLORIDA   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d CIPLA LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ADULT; BIOAVAILABILITY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; PHARMACOKINETICS; THERAPEUTIC EQUIVALENCE;

ADMINISTRATION, INHALATION; ADULT; BIOLOGICAL AVAILABILITY; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RESEARCH DESIGN; THERAPEUTIC EQUIVALENCY;

EID: 84936953257     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-015-9736-6     Document Type: Article

References (24)

1. FDA. Bioavailability and bioequivalence studies for orally administered drug products — general considerations: guidance for Industry. http://www.fdagov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf.2003;1–26.
2. Adams WP, Ahrens RC, Chen M-L, Christopher D, Chowdhury BA, Conner DP, et al. Demonstrating bioequivalence of locally acting orally inhaled drug products (OIPs): workshop summary report. J Aerosol Med Pulm Drug Deliv. 2010;23(1):1–29.
3. O’Connor D, Adams WP, Chen M-L, Daley-Yates P, Davis J, Derendorf H, et al. Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report. J Aerosol Med Pulm Drug Deliv. 2011;24(3):119–35.
4. Rebello J. Challenges in the development of affordable orally inhaled products. 2014. Available from: https://custom.cvent.com/7BA2EE65E8B64AEBB1E77F19E7FD30BC/files/event/8a749091c2c741228907ca5c70b619eb/284b3a1c3f9a4ac2bed09d5c32c34804.pdf.
5. Lionberger R. Interpreting Pharmacokinetics for inhalation Bioequivalence. Orlando. Available from: https://custom.cvent.com/7BA2EE65E8B64AEBB1E77F19E7FD30BC/files/event/8a749091c2c741228907ca5c70b619eb/8571b1c28da74f50a73d9076dfa9215a.pdf (2014).
6. Hochhaus G, Möllmann H. Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992;30(9):342–62.
7. Hindle M, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation [see comments]. Br J Clin Pharmacol. Blackwell Publishing Ltd; 1992;34(4):311–5.
8. Thorsson L, Edsbäcker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994;7(10):1839–44.
9. Edsbäcker S, Wollmer P, Selroos O, Borgström L, Olsson B, Ingelf J. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids? Pulm Pharmacol Ther. 2008;21(2):247–58.
10. Goyal N, Hochhaus G, Dalby RN, Byron PR, Peart J. Demonstrating bioequivalence using pharmacokinetics: theoretical considerations across drug classes. Respiratory Drug Delivery. 2010.
11. Dolovich M, Ryan G, Newhouse MT. Aerosol penetration into the lung; influence on airway responses. Chest. 1981;80(6 Suppl):834–6.
12. Ruffin RE, Dolovich MB, Wolff RK, Newhouse MT. The effects of preferential deposition of histamine in the human airway. Am Rev Respir Dis. 1978;117(3):485–92.
13. EMA. Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP) including the Requirements for Demonstration of their Therapeutic Equivalence between two Inhaled Products for use in the Treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD) [Internet]. 2007 [cited 2010 Jul 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003551.pdf.
14. Wachtel H. IVIVC in Pediatric OIPs [Internet]. Orlando Inhalation Conference. 2014 [cited 2014 Nov 9]. Available from: https://custom.cvent.com/7BA2EE65E8B64AEBB1E77F19E7FD30BC/files/event/8a749091c2c741228907ca5c70b619eb/0a1e8dc4d61b4af6bfedaeb1620f7ec4.pdf.
15. Garcia-Arieta A. In vitro and PK studies for generics based on European experience [Internet]. 2014 [cited 2014 Oct 26]. Available from: https://custom.cvent.com/7BA2EE65E8B64AEBB1E77F19E7FD30BC/files/event/8a749091c2c741228907ca5c70b619eb/f1667a8615fe4a55ad931c409392c08e.pdf.
16. Mendes Lima Santos G. Considerations for generic OIPs in Brazil [Internet]. 2014 [cited 2014 Oct 26]. Available from: https://custom.cvent.com/7BA2EE65E8B64AEBB1E77F19E7FD30BC/files/event/8a749091c2c741228907ca5c70b619eb/98f6e2e31b024eed9c8f81c31b3e9242.pdf.
17. FDA. Draft Guidance on Albuterol Sulfate [Internet]. fda.gov. 2013 [cited 2013 Apr 8]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM346985.pdf.
18. FDA. Draft Guidance on Fluticasone Propionate; Salmeterol Xinafoate http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm367643.pdf.
19. Davit BM, Conner DP, Fabian-Fritsch B, Haidar SH, Jiang X, Patel DT, et al. Highly variable drugs: observations from bioequivalence data submitted to the FDA for new generic drug applications. AAPS J. 2008;10(1):148–56.
20. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US food and drug administration. Springer; 2012;14(4):915–24. Available from: http://www.springerlink.com/index/10.1208/s12248-012-9406-x.
21. FDA. Draft Guidance on Lidocaine [Internet]. 2014 [cited 2014 Nov 11]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm086293.pdf.
22. FDA. Draft Guidance on Mesalamine [Internet]. Drug Discovery World Spring 2006. 2014 [cited 2014 Nov 11]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm319999.pdf.
23. Reisner C. In vitro/in vivo comparisons of formoterol MDI to Formoterol DPI: Lessons learned [Internet]. Orlando Inhalation Conference. 2014 [cited 2014 Oct 26]. Available from: https://custom.cvent.com/7BA2EE65E8B64AEBB1E77F19E7FD30BC/files/event/8a749091c2c741228907ca5c70b619eb/228b0d5a93e34653ab9b033dfc7e54a7.pdf.
24. Horhota ST, Verkleij CB, Cornelissen PJG, Bour L, Sharma A, Trunk M. Case study: pharmacokinetics and pharmacodynamics of tiotropium and salmeterol following parallel administration in COPD patients using different dry powder inhalation systems [Internet]. Orlando Inhalation Conference. 2014 [cited 2014 Oct 26]. Available from: https://custom.cvent.com/7BA2EE65E8B64AEBB1E77F19E7FD30BC/files/event/8a749091c2c741228907ca5c70b619eb/f53ea6bc433a4dbeb1ec47895ba719ef.pdf.